| Literature DB >> 19099564 |
Dragomir P Zubac1, Leif Bostad, Tomas Seidal, Tore Wentzel-Larsen, Svein A Haukaas.
Abstract
BACKGROUND: To investigate a possible prognostic significance of interactions between lymph node invasion (LNI), synchronous distant metastases (SDM), and venous invasion (VI) adjusted for mode of detection, Eastern Cooperative Oncology Group performance status (ECOG PS), erythrocyte sedimentation rate (ESR) and tumour size (TS) in 196 patients with renal cell carcinoma treated with radical nephrectomy.Entities:
Mesh:
Year: 2008 PMID: 19099564 PMCID: PMC2635370 DOI: 10.1186/1471-2490-8-19
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.264
Clinical and pathologic features in 196 patients with renal cell carcinoma.
| Features | Clear cell carcinoma | Papillary carcinoma | All subtypesa |
| No. of cases | 172 (87.8) | 19 (9.7) | 196 (100) |
| Mean age (years) | 66.6 | 62.4 | 66.4 |
| Gender | |||
| n Male/Female | 95/77 | 13/6 | 110/86 (56.1) |
| Pathologic tumour size (cm) | |||
| Median (range) | 7.0 (1.5 – 26.0) | 8 (3.0–20.0) | 7 (1.5 – 26.0) |
| Mode of presentation | |||
| Symptomatic/Incidental | 144/28 | 17/2 | 165/31 (84.2) |
| ECOG performance status: | |||
| 0 | 109 (63.4) | 12 (63.2) | 125 (63.8) |
| 1 | 52 (30,2) | 6 (31.6) | 58 (29.6) |
| 2 | 11 (6.4) | 1 (5.3) | 13 (6.6) |
| ESR | |||
| < 28 mm | 88 (51.2) | 10 (52.5) | 103 (52.6) |
| ≥ 28 mm | 84 (48.8) | 9 (47.3) | 95 (48.5) |
| RCC Stage groups (TNM, 2002) | |||
| I | 52 (30.2) | 7 (36,8) | 62 (31.6) |
| II | 24 (14.0) | 5 (26,3) | 29 (14.8) |
| III | 48 (27.9) | 3 (15.8) | 53 (27.0) |
| IV | 48 (27.9) | 4 (21.1) | 52 (27.0) |
| Primary pathological tumour stage (pT, 2002) | |||
| pT1a | 18 (10.5) | 3 (15,8) | 22 (11.2) |
| pT1b | 39 (22.7) | 5 (26.3) | 46 (23.5) |
| pT2 | 28 (16.3) | 6 (31.6) | 34 (17.3) |
| pT3a | 28 (16.3) | 0 (0) | 29 (14.8) |
| pT3b | 48 (28.0) | 5 (26.3) | 54 (27.6) |
| pT3c | 0 (0) | 0 (0) | 0 (0) |
| pT4 | 11 (6.4) | 0 (0) | 11 (5.6) |
| Pathologic stage of lymph nodes (N, 2002) | |||
| pN x | 141 (82.0) | 15 (79.0) | 161 (82.1) |
| pN 0 | 14 (8.1) | 0 (0) | 14 (7.1) |
| pN 1 | 10 (5.8) | 2 (11.0) | 12 (6.1) |
| pN 2 | 7 (4.1) | 2 (11.0) | 9 (4.6) |
| SDM (M, 2002) | |||
| M 0 | 131 (76.1) | 15 (79.0) | 151 (77.0) |
| M + (single) | 9 (5.2) | 1 (5.3) | 10 (5.1) |
| M + (multiple) | 32 (18.6) | 3 (15.8) | 35 (17.9) |
| Venous invasion (VI = pV1+pV2) | |||
| pV 0 | 122 (70.9) | 14 (73.7) | 140 (71.4) |
| pV 1 (renal vein) | 36 (20.9) | 4 (21.1) | 41 (20.9) |
| pV 2 (vena cava) | 14 (8.1) | 1 (5.3) | 15 (7.7) |
Unless stated otherwise, values shown represent numbers of patients, with percentages in parentheses.
aIncluding chromophobic carcinoma (n = 5)
Univariate analysis of cancer specific survival related to clinicopathological variables in 196 patients operated with radical nephrectomy for renal cell carcinoma.
| UNIVARIATE ANALYSIS | Cancer specific survival | ||
| HR | 95% CI | p-value | |
| Primary pathological tumour stage (pT, 2002) | |||
| pT1a ref. | |||
| pT1b | 5.5 | 0,7 – 42.7 | 0.102 |
| pT2 | 11.5 | 1,5 – 87.6 | 0.018 |
| pT3a | 16.3 | 2.2 – 123.5 | 0.007 |
| pT3b | 21.5 | 2.9 – 157.1 | 0.003 |
| pT4 | 63.5 | 8.1 – 498.2 | <0.001 |
| Gender male ref. | 0.74 | 0.48 – 1.14 | 0.170 |
| Age (continuous), per 5 years | 1.01 | 0.91 – 1.11 | 0.908 |
| Continuously coded tumour size (CCTS), per 10 cm | 2.98 | 1.87 – 4.75 | <0.001 |
| Mode of detection (Incidental vs. Symptomatic) | 3.89 | 1.58 – 9.59 | 0.003 |
| ECOG PS (≥ 1 vs. 0) | 1.94 | 1.26 – 2.98 | 0.002 |
| ESR (≥ 28 mm vs. < 28 mm) | 3.36 | 2.11 – 5.35 | <0.001 |
| LNI (pN 1/2 vs. pN x/0) | 5.38 | 3.17 – 9.10 | <0.001 |
| SDM (M + vs. M 0) | 6.56 | 4.17 – 10.33 | <0.001 |
| VI (pV 1/2 vs. pV 0) | 2.33 | 1.51 – 3.60 | <0. 001 |
Multivariate survival analysis of interactions between clinicopathological variables and cancer specific survival in 196 patients operated with radical nephrectomy for renal cell carcinoma.
| MULTIVARIATE | Cancer specific survival | ||
| ANALYSES | HR | 95% CI | p-value |
| Lymph Node Involvement present | |||
| VI present, SDM present | 0.55 | 0.23 – 1.30 | 0.173 |
| VI present, SDM absent | 2.78 | 0.80 – 9.64 | 0.108 |
| VI absent, SDM present | 1.77 | 0.74 – 4.21 | 0.197 |
| VI absent, SDM absent | 8.96 | 3.27 – 24.56 | <0.001 |
| Venous invasion present | |||
| LNI present | 0.63 | 0.25 – 1.64 | 0.349 |
| LNI absent | 2.05 | 1.22 – 3.43 | 0.006 |
| Synchronous distant metastases present | |||
| LNI present | 0.93 | 0.32 – 2.74 | 0.894 |
| LNI absent | 4.71 | 2.68 – 8.27 | <0.001 |
| CCTS (Tumour size per 10 cm) | 1.49 | 0.75 – 2.95 | 0.256 |
| ESR (≥ 28 mm vs. <28 mm ref.) | 1.94 | 1.15 – 3.26 | 0.012 |
| ECOG PS (≥ 1 vs. 0) | 1.47 | 0.93 – 2.33 | 0.099 |
| Mode of detection (Symptomatic vs. Incidental) | 0.66 | 0.25 – 1.71 | 0.392 |
Figure 1Kaplan-Meier analyses of cancer specific survival in 175 lymph node negative renal cell carcinoma patients by different combinations of synchronous distant metastases (SDM) and venous invasion (VI) and in 21 patients with lymph node positive renal cell carcinoma.